Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma Launches Olanzapine and Olanzapine ODT
Details :
Product Name : Zyprexa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HEC88473
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Apollo Therapeutics
Deal Size : $938.0 million
Deal Type : Licensing Agreement
Apollo Licenses FGF21/GLP-1 Agonist from Sunshine Lake for Multi-Indications
Details :
Product Name : APL-18881
Product Type : Other Large Molecule
Upfront Cash : $12.0 million
December 11, 2024
Lead Product(s) : HEC88473
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Apollo Therapeutics
Deal Size : $938.0 million
Deal Type : Licensing Agreement
Lead Product(s) : K1.1 mRNA
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma Reports K1.1 mRNA Breakthrough for Liver Cancer Therapy
Details :
Product Name : K1.1 mRNA
Product Type : Vaccine
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : K1.1 mRNA
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma Launches a New Generic Prescription Drug
Details :
Product Name : Urso DS-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2024
Lead Product(s) : Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Jewish General Hospital
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : Adva-27a
Product Type : Protein
Upfront Cash : Undisclosed
October 02, 2023
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Jewish General Hospital
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : K1.1
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Details :
Product Name : K1.1
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
November 16, 2022
Lead Product(s) : K1.1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Adva-27a
Product Type : Protein
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SBFM-PL4
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Arizona
Deal Size : Undisclosed
Deal Type : Collaboration
Details :
Product Name : SBFM-PL4
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 25, 2022
Lead Product(s) : SBFM-PL4
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Arizona
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Adva-27a
Product Type : Protein
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Adva-27a
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable